{"filing":{"accession_number":"0001104659-26-071000","cik":"0001818382","ticker":"HUMAW","company_name":"Humacyte, Inc.","form":"8-K","filing_date":"2026-06-05","report_date":null,"primary_document":"tm2616944d2_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1818382/000110465926071000/tm2616944d2_8k.htm"},"events":[{"id":6418,"run_id":5621,"accession_number":"0001104659-26-071000","anchor_item_number":"8.01","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.95,"summary":"Humacyte disclosed receipt of a Nasdaq deficiency notice on May 4, 2026, for failure to maintain the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5450(a)(1), followed by notification on June 5, 2026, that the company had regained compliance. This disclosure directly addresses delisting risk and continued listing status, which is material to investors assessing the registrant's ability to remain publicly traded.","company_name":"Humacyte, Inc.","ticker":"HUMAW","filing_date":"2026-06-05","submitted_at":null,"items":[{"id":4872,"accession_number":"0001104659-26-071000","item_number":"8.01","item_title":"Other Events.","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.95,"reasoning":"Humacyte disclosed receipt of a Nasdaq deficiency notice on May 4, 2026, for failure to maintain the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5450(a)(1), followed by notification on June 5, 2026, that the company had regained compliance. This disclosure directly addresses delisting risk and continued listing status, which is material to investors assessing the registrant's ability to remain publicly traded.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T20:33:29.931100+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":4872,"accession_number":"0001104659-26-071000","item_number":"8.01","item_title":"Other Events.","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.95,"reasoning":"Humacyte disclosed receipt of a Nasdaq deficiency notice on May 4, 2026, for failure to maintain the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5450(a)(1), followed by notification on June 5, 2026, that the company had regained compliance. This disclosure directly addresses delisting risk and continued listing status, which is material to investors assessing the registrant's ability to remain publicly traded.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T20:33:29.931100+00:00","company_name":"Humacyte, Inc.","ticker":"HUMAW","filing_date":"2026-06-05"}]}